[go: up one dir, main page]

GT201200341A - Utilizaciòn de la asociaciòn de un ihibidor de la correinte sinusal if y de un inhibidor de la enzima de conversiòn de la angiotensina para el tratamiento de la insuficiencia cardiaca - Google Patents

Utilizaciòn de la asociaciòn de un ihibidor de la correinte sinusal if y de un inhibidor de la enzima de conversiòn de la angiotensina para el tratamiento de la insuficiencia cardiaca

Info

Publication number
GT201200341A
GT201200341A GT201200341A GT201200341A GT201200341A GT 201200341 A GT201200341 A GT 201200341A GT 201200341 A GT201200341 A GT 201200341A GT 201200341 A GT201200341 A GT 201200341A GT 201200341 A GT201200341 A GT 201200341A
Authority
GT
Guatemala
Prior art keywords
inhibitor
heart failure
sinusal
association
treatment
Prior art date
Application number
GT201200341A
Other languages
English (en)
Inventor
Thuillez Christian
Mulder Paulus
Vilaine Jean Paul
Fratacci Marie-Dominique
Lerebours-Pigeonniere Guy
Feldmann Luc
Roussel Jèr Me
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200341(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200341A publication Critical patent/GT201200341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UTILIZACIÓN DE LA ASOCIACIÓN DE UN INHIBIDOR SELECTIVO Y ESPECÍFICO DE LA CORRIENTE SINUSAL IF, MÁS PARTICULARMENTE LA IVABRADINA O LA N-{[(7S)-3,4-DIMETOXIBICICLO[4.2.0]OCTA-1,3,5-TRIEN-7-IL]METIL}-3-(7,8-DIMETOXI-1,2,4,5-TETRAHIDRO-3H-3-BENZAZEPIN-3-IL)-N-METIL-3-OXO-1-PROPANAMINA Y DE UN AGENTE INHIBIDOR DE LA ENZIMA DE CONVERSIÓN DE LA ANGIOTENSINA PARA LA OBTENCIÓN DE MEDICAMENTOS DESTINADOS AL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA, MÁS PARTICULARMENTE DE LA INSUFICIENCIA CARDIACA CON FUNCIÓN SISTÓLICA CONSERVADA.
GT201200341A 2010-06-15 2012-12-14 Utilizaciòn de la asociaciòn de un ihibidor de la correinte sinusal if y de un inhibidor de la enzima de conversiòn de la angiotensina para el tratamiento de la insuficiencia cardiaca GT201200341A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1002525A FR2961105B1 (fr) 2010-06-15 2010-06-15 Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque

Publications (1)

Publication Number Publication Date
GT201200341A true GT201200341A (es) 2014-03-14

Family

ID=42985210

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200341A GT201200341A (es) 2010-06-15 2012-12-14 Utilizaciòn de la asociaciòn de un ihibidor de la correinte sinusal if y de un inhibidor de la enzima de conversiòn de la angiotensina para el tratamiento de la insuficiencia cardiaca

Country Status (47)

Country Link
US (1) US20110306598A1 (es)
EP (2) EP2921168B1 (es)
JP (1) JP5480202B2 (es)
KR (1) KR101389879B1 (es)
CN (2) CN104906579A (es)
AP (2) AP3691A (es)
AR (1) AR081875A1 (es)
AU (1) AU2011202607B2 (es)
BR (1) BRPI1102830F1 (es)
CA (1) CA2743527C (es)
CL (1) CL2011001420A1 (es)
CO (1) CO6640265A2 (es)
CR (1) CR20120609U (es)
CU (1) CU24161B1 (es)
CY (2) CY1116438T1 (es)
DK (2) DK2921168T3 (es)
EA (1) EA022612B1 (es)
EC (1) ECSP12012337A (es)
ES (2) ES2582157T3 (es)
FR (1) FR2961105B1 (es)
GE (1) GEP20146132B (es)
GT (1) GT201200341A (es)
HK (1) HK1210012A1 (es)
HR (2) HRP20150745T1 (es)
HU (2) HUE027788T2 (es)
IL (1) IL223293A (es)
JO (1) JO3309B1 (es)
MA (1) MA33235B1 (es)
ME (2) ME02476B (es)
MX (1) MX2011006001A (es)
MY (1) MY179034A (es)
NI (1) NI201200182A (es)
NZ (2) NZ593437A (es)
PE (1) PE20120019A1 (es)
PH (1) PH12012502315B1 (es)
PL (2) PL2921168T3 (es)
PT (1) PT2404600E (es)
RS (2) RS54077B1 (es)
SA (2) SA114360089B1 (es)
SG (2) SG10201500502WA (es)
SI (2) SI2404600T1 (es)
TN (1) TN2012000551A1 (es)
TW (1) TWI468164B (es)
UA (1) UA108983C2 (es)
UY (1) UY33423A (es)
WO (1) WO2011157908A1 (es)
ZA (1) ZA201104222B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603666A (zh) * 2012-02-28 2012-07-25 石河子大学 肉桂酰牛磺酰噻唑烷酸类化合物及其应用
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
EP3025705B8 (en) * 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
PH12018502155B1 (en) 2016-04-20 2024-03-27 Servier Lab Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
KR20190001340A (ko) * 2017-06-27 2019-01-04 에리슨제약(주) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법
CN107550915A (zh) * 2017-10-31 2018-01-09 泰州中国医药城中医药研究院 一种伊伐布雷定和咯利普兰组合物及其在制药中的应用
CN107714702A (zh) * 2017-10-31 2018-02-23 泰州中国医药城中医药研究院 一种伊伐布雷定和米力农组合物及其在制药中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
US6188743B1 (en) * 1997-10-10 2001-02-13 Analogic Corporation Computed tomography scanner drive system and bearing
FR2807431B1 (fr) * 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
FR2838648B1 (fr) 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
BRPI0516128A (pt) * 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
EP1912666A2 (en) * 2005-07-22 2008-04-23 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
FR2920773B1 (fr) 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2921365B1 (fr) 2007-09-21 2012-10-12 Servier Lab Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2927538B1 (fr) * 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
RU2364401C1 (ru) * 2008-05-12 2009-08-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции сосудистого ремоделирования у больных хронической сердечной недостаточностью ишемической этиологии
WO2009158005A1 (en) * 2008-06-27 2009-12-30 Concert Pharmaceuticals, Inc. Benzazepinone compounds
RU2382644C1 (ru) 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью

Also Published As

Publication number Publication date
MX2011006001A (es) 2011-12-14
SG177069A1 (en) 2012-01-30
HK1210011A1 (zh) 2016-04-15
CU20120166A7 (es) 2013-04-19
CY1116438T1 (el) 2017-02-08
JP2012001545A (ja) 2012-01-05
RS54077B1 (sr) 2015-10-30
NZ600931A (en) 2013-04-26
BRPI1102830A2 (pt) 2013-12-24
CN102284060A (zh) 2011-12-21
NI201200182A (es) 2013-05-13
ME02476B (me) 2017-02-20
PE20120019A1 (es) 2012-02-11
ES2545343T3 (es) 2015-09-10
TWI468164B (zh) 2015-01-11
IL223293A0 (en) 2013-02-03
ECSP12012337A (es) 2012-12-28
NZ593437A (en) 2012-08-31
ME02163B (me) 2015-10-20
UY33423A (es) 2011-12-30
SA111320527B1 (ar) 2015-03-19
AP2016009002A0 (en) 2016-01-31
CN104906579A (zh) 2015-09-16
SA114360089B1 (ar) 2016-02-03
AU2011202607B2 (en) 2015-02-12
EA022612B1 (ru) 2016-02-29
BRPI1102830B8 (pt) 2020-01-07
BRPI1102830B1 (pt) 2019-10-08
SG10201500502WA (en) 2015-03-30
HUE027088T2 (en) 2016-08-29
SI2921168T1 (sl) 2016-08-31
DK2921168T3 (en) 2016-08-01
ZA201104222B (en) 2012-02-29
SI2404600T1 (sl) 2015-10-30
CR20120609U (es) 2013-02-05
EP2404600B1 (fr) 2015-05-27
CL2011001420A1 (es) 2012-07-06
US20110306598A1 (en) 2011-12-15
CY1117724T1 (el) 2017-05-17
AP2013006661A0 (en) 2013-01-31
PH12012502315A1 (en) 2013-02-04
MA33235B1 (fr) 2012-05-02
PL2921168T3 (pl) 2016-10-31
FR2961105A1 (fr) 2011-12-16
CU24161B1 (es) 2016-03-31
JP5480202B2 (ja) 2014-04-23
EP2921168B1 (fr) 2016-04-13
PH12012502315B1 (en) 2020-09-18
AU2011202607A1 (en) 2012-01-12
RS54838B1 (sr) 2016-10-31
AR081875A1 (es) 2012-10-24
FR2961105B1 (fr) 2013-02-08
CA2743527C (fr) 2016-08-02
HRP20160643T1 (hr) 2016-07-01
EA201100773A1 (ru) 2011-12-30
MY179034A (en) 2020-10-26
UA108983C2 (en) 2015-07-10
CA2743527A1 (fr) 2011-12-15
GEP20146132B (en) 2014-08-11
IL223293A (en) 2017-04-30
DK2404600T3 (en) 2015-08-31
AP3691A (en) 2016-04-30
ES2582157T3 (es) 2016-09-09
KR20110136752A (ko) 2011-12-21
TW201206445A (en) 2012-02-16
HK1210012A1 (en) 2016-04-15
EP2404600A1 (fr) 2012-01-11
PL2404600T3 (pl) 2015-10-30
HRP20150745T1 (hr) 2015-08-14
PT2404600E (pt) 2015-07-13
WO2011157908A1 (fr) 2011-12-22
JO3309B1 (ar) 2018-09-16
TN2012000551A1 (fr) 2014-04-01
CO6640265A2 (es) 2013-03-22
WO2011157908A8 (fr) 2013-01-17
BRPI1102830F1 (pt) 2022-03-29
HUE027788T2 (en) 2016-10-28
KR101389879B1 (ko) 2014-04-29
EP2921168A1 (fr) 2015-09-23

Similar Documents

Publication Publication Date Title
GT201200341A (es) Utilizaciòn de la asociaciòn de un ihibidor de la correinte sinusal if y de un inhibidor de la enzima de conversiòn de la angiotensina para el tratamiento de la insuficiencia cardiaca
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
IN2012DN01869A (es)
MA32774B1 (fr) Antagonistes de récepteur de mélanocortine
IT1397599B1 (it) Convertitore flyback dual mode e metodo di controllo della modalita' di funzionamento.
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
IL222252A (en) A system, device and method for detecting and diagnosing biological arrhythmias
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
SI2687506T1 (sl) Postopek za encimsko sintezo (7S)-1-(3,4-dimetoksibiciklo(4.2.0)okta-1,3,5-trien-7-il) N-metil metanamina ter uporaba za sintezo ivabradina in njegovih soli
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4
SI2626428T1 (sl) Postopek za encimsko sintezo (7S)-3,4-dimetoksibiciklo(4.2.0)okta-1,3, 5-trien-7-karboksilne kisline ali njenih estrov ter uporaba sinteze ivabradina in njegovih soli
GT200600522A (es) Nueva asociación de un inhibidor de la corriente sinusal i, y de un inhibidor de la enzima de conversión y las composiciones farmacéuticas que la contienen
EA201100132A1 (ru) Единичная доза ападеносона
NZ618644A (en) New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
AU323239S (en) Bath chair
HRP20150950T1 (en) Method for enzymatic synthesis of (7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid, and use for the synthesis of ivabradine and the salts thereof
LV14361A (lv) Līdzeklis fagocitārās aktivitātes paaugstināšanai
UA43993U (en) S-derivatives of 5-r-4-r1-1,2,4-triazole-3-thione exhibiting anti-inflammatory activity
CU23732A3 (es) Nueva asociación de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversión
UA100553C2 (ru) Способ оценки эффективности лечения исрадипином больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
AU323752S (en) Lighting assembly
AU323751S (en) Lighting assembly